SCHEMBL15575243

SCHEMBL15575243

CCOc1ccc(C(F)(F)F)cc1NC(=O)NCc1ccc(Oc2ccnc(C(=O)O)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDR2 Q16832 3/20 0.63
RAF1 P04049 8/20 0.59
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.45
KDR P35968 2/20 0.44
PLK4 O00444 1/20 0.44
AURKA O14965 1/20 0.44
MAPK13 O15264 1/20 0.44
JAK2 O60674 1/20 0.44
MAP4K4 O95819 1/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
LYN P07948 1/20 0.44
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990724 0.92 RAF1 (0.67) DDR2RAF1KMT2AL3MBTL1
SCHEMBL15573225 0.92 DDR2 (0.74) DDR2RAF1CYP1A2CYP2C9CYP2C19
SCHEMBL15574167 0.91 DDR2 (0.62) DDR2RAF1KMT2AKDRPLK4
SCHEMBL16990681 0.91 DDR2 (0.56) DDR2RAF1CYP1A2CYP2C9CYP2C19
SCHEMBL16990618 0.91 DDR2 (0.60) DDR2RAF1KMT2AKDRPLK4
SCHEMBL16990585 0.90 DDR2 (0.62) DDR2RAF1KMT2AKDRPLK4
SCHEMBL16990712 0.90 DDR2 (0.60) DDR2RAF1KDRPLK4AURKA
SCHEMBL16990661 0.90 DDR2 (0.59) DDR2RAF1KDRPLK4AURKA
SCHEMBL16990601 0.90 DDR2 (0.59) DDR2RAF1KDRPLK4AURKA
SCHEMBL16990714 0.90 DDR2 (0.58) DDR2RAF1KDRPLK4AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 DDR2 1/4885RAF1 3072/4885CYP1A2 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.